Prana Biotechnology Limited soars on positive news: Is it a spec buy?

Prana Biotechnology Limited (ASX:PBT) has jumped in trade today.

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Huntington's and Alzheimer's diseases are often described as being among the last great frontiers modern medicine has yet to deliver effective treatments for. However, Aussie biotech business Prana Biotechnology Limited (ASX: PBT) has long trumpeted its PBT2 drug as one potential treatment and today announced it has received Orphan designation from the European Commission for PBT2 for the treatment of Huntington's.

Orphan drug designation gives the business additional support in trialling the drug and a ten-year period of market exclusivity if the drug were ever approved for commercialisation.

The company also has Orphan drug designation with the US Food and Drug Administration (FDA) and recently announced what it says were positive results for a Phase II clinical trial for Huntington's.

However, it's the neuro-degenerative and genetic nature of diseases like Huntington's that has curtailed attempts to develop an effective treatment so far, with some medical professionals even on record as suggesting an effective treatment will never be developed.

Although, the stock has jumped 6 cents or 33% to 24 cents on today's news, which shows just how happy some investors are to back a biotech growth story even when the odds against it remain strong.

Notably in early 2014 the stock soared to $1.26 as the company and others talked up its chances of success in developing a cure for Alzheimer's. However, once the Phase II trial results showed the drugs were largely ineffective in their trial goals the stock crashed around 80% to near today's levels.

That experience suggests only the most gullible of investors will bid the stock up much higher in the expectation that the company is now on the path to blockbuster success. That's not impossible, but history suggests investors should be aware of the risks and treat the company's prospects with a healthy dose of scepticism.

Another company that's been on a wild ride recently is Prima Biomed Limited (ASX: PRR), although it also looks a risky prospect as it attempts to pioneer immuno-oncology therapies.

Why would a smart investor chase a biotech stock with the odds stacked against it when they could buy a gangbusters growth stock on an attractive valuation with the odds of success looking genuinely strong…

Motley Fool contributor Tom Richardson has no position in any stocks mentioned. You can find Tom on Twitter @tommyr345 The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »